163 related articles for article (PubMed ID: 33230179)
21. Protein dynamics analysis identifies candidate cancer driver genes and mutations in TCGA data.
Sayılgan JF; Haliloğlu T; Gönen M
Proteins; 2021 Jun; 89(6):721-730. PubMed ID: 33550612
[TBL] [Abstract][Full Text] [Related]
22. High prevalence of cancer-associated TP53 variants in the gnomAD database: A word of caution concerning the use of variant filtering.
Soussi T; Leroy B; Devir M; Rosenberg S
Hum Mutat; 2019 May; 40(5):516-524. PubMed ID: 30720243
[TBL] [Abstract][Full Text] [Related]
23. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
[TBL] [Abstract][Full Text] [Related]
24. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
25. [TP53 mutations and hematological malignancies].
Hirabayashi S; Misato S; Manabe A
Rinsho Ketsueki; 2018; 59(11):2468-2474. PubMed ID: 30531145
[TBL] [Abstract][Full Text] [Related]
26. Seshat: A Web service for accurate annotation, validation, and analysis of TP53 variants generated by conventional and next-generation sequencing.
Tikkanen T; Leroy B; Fournier JL; Risques RA; Malcikova J; Soussi T
Hum Mutat; 2018 Jul; 39(7):925-933. PubMed ID: 29696732
[TBL] [Abstract][Full Text] [Related]
27. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
28. Understanding human DNA variants affecting pre-mRNA splicing in the NGS era.
Dufner-Almeida LG; do Carmo RT; Masotti C; Haddad LA
Adv Genet; 2019; 103():39-90. PubMed ID: 30904096
[TBL] [Abstract][Full Text] [Related]
29. Somatic TP53 Mutations in the Era of Genome Sequencing.
Hainaut P; Pfeifer GP
Cold Spring Harb Perspect Med; 2016 Nov; 6(11):. PubMed ID: 27503997
[TBL] [Abstract][Full Text] [Related]
30. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data.
Bouaoun L; Sonkin D; Ardin M; Hollstein M; Byrnes G; Zavadil J; Olivier M
Hum Mutat; 2016 Sep; 37(9):865-76. PubMed ID: 27328919
[TBL] [Abstract][Full Text] [Related]
31. Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
Manoharan V; Karunanayake EH; Tennekoon KH; De Silva S; Imthikab AIA; De Silva K; Angunawela P; Vishwakula S; Lunec J
BMC Cancer; 2020 Jan; 20(1):72. PubMed ID: 32000721
[TBL] [Abstract][Full Text] [Related]
32. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
33. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
[TBL] [Abstract][Full Text] [Related]
34. Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer.
Narayan S; Bader GD; Reimand J
Genome Med; 2016 May; 8(1):55. PubMed ID: 27175787
[TBL] [Abstract][Full Text] [Related]
35. TP53 mutations in human cancer: database reassessment and prospects for the next decade.
Leroy B; Anderson M; Soussi T
Hum Mutat; 2014 Jun; 35(6):672-88. PubMed ID: 24665023
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing.
Cheng DT; Prasad M; Chekaluk Y; Benayed R; Sadowska J; Zehir A; Syed A; Wang YE; Somar J; Li Y; Yelskaya Z; Wong D; Robson ME; Offit K; Berger MF; Nafa K; Ladanyi M; Zhang L
BMC Med Genomics; 2017 May; 10(1):33. PubMed ID: 28526081
[TBL] [Abstract][Full Text] [Related]
37. TP53 protein expression analysis by luminometric immunoassay in comparison with gene mutation status and prognostic factors in early stage endometrial cancer.
Koul A; Bendahl PO; Borg A; Fernö M; Lidebring MF; Högberg T; Einarsson EL; Ridderheim M; Willén R
Int J Gynecol Cancer; 2002; 12(4):362-71. PubMed ID: 12144684
[TBL] [Abstract][Full Text] [Related]
38. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage.
Zerdoumi Y; Lanos R; Raad S; Flaman JM; Bougeard G; Frebourg T; Tournier I
Hum Mol Genet; 2017 Jul; 26(14):2591-2602. PubMed ID: 28369373
[TBL] [Abstract][Full Text] [Related]
39. Genetic and functional studies of a germline TP53 splicing mutation in a Li-Fraumeni-like family.
Varley JM; Chapman P; McGown G; Thorncroft M; White GR; Greaves MJ; Scott D; Spreadborough A; Tricker KJ; Birch JM; Evans DG; Reddel R; Camplejohn RS; Burn J; Boyle JM
Oncogene; 1998 Jun; 16(25):3291-8. PubMed ID: 9681828
[TBL] [Abstract][Full Text] [Related]
40. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
